Metropolitan Life Insurance Company (MetLife)’s Black Diamond Therapeutics BDTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,594	Closed	-$136K	–	2728
2021 Q1	$136K	Hold	5,594	–	–	﹤0.01%	2274
2020 Q4	$179K	Hold	5,594	–	–	﹤0.01%	2006
2020 Q3	$169K	Buy	5,594 +1,127	+25%	+$34.3K	﹤0.01%	1881
2020 Q2	$188K	Hold	4,467	–	–	﹤0.01%	1841
2020 Q1	$111K	Buy	+4,467	New	+$136K	﹤0.01%	1972

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s BDTX Position: Q2 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 5,594 shares — an estimated $136K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in BDTX in Q1 2020 and held it in 5 quarters. The position peaked at $188K in Q2 2020. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

Metropolitan Life Insurance Company (MetLife) reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 5,594 Black Diamond Therapeutics shares in Q2 2021, an estimated $136K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 5 quarters.
Metropolitan Life Insurance Company (MetLife)'s Black Diamond Therapeutics position peaked at $188K in Q2 2020.
102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2021, filed 16 Aug 2021.